**Instructions**:

1. **AoU Relevance**:

   - `"aou_related": true` if the paper mentions or uses AoU data (including AoU infrastructure, protocols, or results).
   - If `true`, provide details about how AoU data is incorporated.
   - If `false`, fill AoU-related fields with `"Not applicable"`.

2. **Core Information**:

   - **Paper Type**: Choose one:
     - `"paper_type": "Research"`, `"Review"`, `"Tool"`, `"Tutorial"`, `"Benchmark"`, `"Protocol"`, `"Other"`

   - **Scientific Impact** (1–5):
     - 1: Minor contribution
     - 2: Limited
     - 3: Notable advancement
     - 4: Field-changing
     - 5: Breakthrough
     - Include `"scientific_impact_note"` to explain the rating.

   - **Scientific Intent**:
     - `"scientific_intent"`: Choose one or more categories that describe the paper’s primary objective:
       - "Population health analysis"
       - "Disease association study"
       - "Method/analysis development"
       - "Data resource description"
       - "Replication/validation study"
       - "Meta-analysis"
       - "Policy/ethics discussion"
       - "Other"
     - `"scientific_intent_note"`: Add free-text details on the study’s aims.

   - **AoU Role**:
     - `"aou_role"`: If `aou_related` is true, categorize AoU’s involvement:
       - "Primary dataset" (AoU data is the main source)
       - "Secondary dataset" (AoU data complements another dataset)
       - "Comparison dataset" (AoU data used for benchmarking or comparison)
       - "Mentioned but not used" (Paper discusses AoU but no data analysis from AoU)
       - "Other"
     - `"aou_role_note"`: Provide details on how AoU data/program is integrated into the study.

   - **AoU Data Scope**:
     - If `aou_related` is true, `"aou_data_scope"`: 
       - "Genomic data"
       - "EHR/phenotypic data"
       - "Both genomic and phenotypic"
       - "Not specified"
       - "Other"
     - `"aou_data_scope_note"`: Explain what aspects of AoU data were used.

   - **Study Population/Demographics**:
     - `"study_population_note"`: Describe the population studied, including demographics, if applicable.  
       (For AoU, this might include diversity aspects, though details may vary.)

   - **Comparison with Other Cohorts or Studies**:
     - `"comparison_with_other_cohorts": true` or `false`.
     - If `true`, `"comparison_with_other_cohorts_note"`: List or describe other cohorts/studies and how AoU compares.
     - `"comparison_sets"`: An array of arrays, each inner array listing cohorts or datasets compared.

3. **Data and Methodologies**:

   - **Data Types**:
     - `"data_types_used"`: List any data types relevant to the study:
       - "Whole-genome sequencing"
       - "Exome sequencing"
       - "RNA-Seq"
       - "ATAC-Seq"
       - "ChIP-Seq"
       - "Metagenomics"
       - "EHR data"
       - "Survey data"
       - "Imaging data"
       - "Biometric data"
       - "Other"
     - `"data_types_note"`: Any clarification about the chosen data types.

   - **Methodological Details**:
     - `"methodological_details"`: Array of relevant methodologies used:
       - "Variant calling", "GWAS", "Machine learning", "Quality control", "Comparative analysis", "Population structure analysis", "Functional annotation", "Statistical modeling", "Data integration", "Other"
     - `"methodological_details_note"`: Additional context on methods.

   - **Software and Tools Used**:
     - `"software_used"`: List of dictionaries describing software/tools used.
       - Each dictionary:
         - `"software_name"`: Name of the software/tool (e.g., "PLINK", "SAIGE", "Hail", "R", "Python", "Bioconductor packages", etc.)
         - `"version"`: Version, or `"Not specified"`
         - `"notes"`: Additional info (usage context, purpose)
     - `"software_used_note"`: Additional context on software usage.

4. **Technical and Infrastructure Details**:

   - **Pipeline/Workflow**:
     - `"pipeline_engine"`: One or more:
       - "WDL", "CWL", "Snakemake", "Nextflow", "Not applicable", "Other"
     - `"pipeline_integration"`: "Standalone", "Integrated", "Modular", "Not applicable"
     - `"pipeline_integration_note"`: Details about how workflows or pipelines are arranged.

   - **Computational Resources**:
     - `"computational_resources"`: Array of:
       - "High-performance computing", "Cloud computing", "Local cluster", "Other"
     - `"computational_resources_note"`: Details on computational setups.

   - **Sequencing Technology**:
     - `"sequencing_technology"`: List of dictionaries:
       - `"company_name"`: e.g., "Illumina", "Oxford Nanopore", "PacBio"
       - `"machine_model"`: Model (e.g., "NovaSeq 6000")
       - `"read_length"`: e.g., "150 bp", or `"Not specified"`
       - `"protocol"`: e.g., "Paired-end", "Long-read"
       - `"notes"`: Additional details

   - **Long-Read Technology Related**:
     - `"long_read_technology_related": true` or `false`.

5. **Contextual and Administrative**:

   - **Publication Date**:
     - `"publication_year"`: numeric
     - `"publication_month"`: numeric (1–12)

   - **DOI**:
     - `"doi"`: Digital Object Identifier string

   - **Journal Impact Factor**:
     - `"journal_impact_factor"`: numeric or `"Not specified"`

   - **Funding Sources**:
     - `"funding_sources"`: Array of:
       - "Government agency", "Private organization", "Institutional", "International organization", "Other"

   - **Open Access**:
     - `"open_access": true` or `false`.

   - **Ethical Considerations**:
     - `"ethical_considerations": true` or `false`.
     - `"ethical_considerations_note"`: If mentioned, provide details.

   - **Data Access and Approvals**:
     - `"data_access_note"`: Mention if AoU data access approvals, IRB approvals, or special permissions are described.

6. **Impact, Intent, and Future Directions**:

   - **User Community Impact** (1–3):
     - `"user_community_impact": 1` (Minimal), `2` (Moderate), `3` (High)
     - `"user_community_impact_note"`: Explain the expected impact on users.

   - **Reproducibility** (1–3):
     - `"reproducibility": 1` (Low), `2` (Moderate), `3` (High)
     - `"reproducibility_note"`: Describe available resources (data/code) for replication.

   - **Future Directions**:
     - `"future_directions_note"`: Potential follow-up studies, expansions, or improvements suggested by the authors.

   - **Study Summary**:
     - `"summary_of_study_note"`: A concise summary of the study’s main focus, findings, and relevance to AoU.

---

**Formatting Guidelines**:

- Use arrays for fields that may contain multiple values.
- Use dictionaries for complex structures (e.g., software, sequencing technology).
- Provide `_note` fields for qualitative, free-text explanations.
- Ensure all fields adhere to the specified categories and terms.
- Strive for clarity, consistency, and comprehensive coverage.
- Use controlled vocabularies where suggested to maintain standardization.

---

**Example JSON**:

```json
{
  "aou_related": true,
  "paper_type": "Research",
  "scientific_impact": 3,
  "scientific_impact_note": "Notable advancement in understanding of population health using AoU data.",
  "scientific_intent": ["Disease association study", "Population health analysis"],
  "scientific_intent_note": "A GWAS on AoU participants focusing on type 2 diabetes prevalence.",
  "aou_role": "Primary dataset",
  "aou_role_note": "AoU genomic and EHR data formed the core dataset.",
  "aou_data_scope": "Both genomic and phenotypic",
  "aou_data_scope_note": "Used AoU WGS and EHR records for demographic and clinical traits.",
  "study_population_note": "Included ~50,000 diverse AoU participants, ensuring broad ancestry representation.",
  "comparison_with_other_cohorts": true,
  "comparison_with_other_cohorts_note": "Compared AoU results with UK Biobank data.",
  "comparison_sets": [
    ["AoU", "UK Biobank"]
  ],
  "data_types_used": ["Whole-genome sequencing", "EHR data"],
  "data_types_note": "WGS for genetic variants and EHR for clinical phenotypes.",
  "methodological_details": ["GWAS", "Quality control", "Population structure analysis"],
  "methodological_details_note": "Used PCA for ancestry correction, standard GWAS QC pipelines.",
  "software_used": [
    {
      "software_name": "Hail",
      "version": "0.2",
      "notes": "Used for scalable GWAS and variant annotation."
    },
    {
      "software_name": "PLINK",
      "version": "1.9",
      "notes": "GWAS QC and basic association tests."
    }
  ],
  "pipeline_engine": ["WDL"],
  "pipeline_integration": "Integrated",
  "pipeline_integration_note": "Combined QC, variant calling, and association steps under one WDL pipeline.",
  "computational_resources": ["Cloud computing"],
  "computational_resources_note": "Used Google Cloud Platform for scalable computation.",
  "sequencing_technology": [
    {
      "company_name": "Illumina",
      "machine_model": "NovaSeq 6000",
      "read_length": "150 bp",
      "protocol": "Paired-end",
      "notes": "Standard AoU WGS protocol"
    }
  ],
  "long_read_technology_related": false,
  "publication_year": 2023,
  "publication_month": 7,
  "doi": "10.1000/exampledoi",
  "journal_impact_factor": 10.2,
  "funding_sources": ["Government agency"],
  "open_access": true,
  "ethical_considerations": true,
  "ethical_considerations_note": "AoU IRB approvals and data use agreements mentioned.",
  "data_access_note": "Accessed AoU data via the Researcher Workbench under approved protocol.",
  "user_community_impact": 2,
  "user_community_impact_note": "Moderate; findings may inform clinicians and researchers interested in genetic risk factors.",
  "reproducibility": 3,
  "reproducibility_note": "Code and summary statistics provided in supplementary materials.",
  "future_directions_note": "Future expansions to include imaging and metabolomic data from AoU.",
  "summary_of_study_note": "A GWAS using AoU genomic and EHR data identifies novel risk loci for type 2 diabetes."
}
